During the submission process, you will be asked to select one topic category for your abstract. The topic category is the general theme under which the abstract will be reviewed and later assigned to themed sessions (if accepted).

All abstracts must be submitted electronically through the Congress management system.

• Abstracts can only be submitted in English.
• The abstract allows a maximum of 10 authors and corresponding affiliations. If your research includes more than 10 authors, please provide additional details in the study group list and limit the author list in the abstract to those who were primarily involved in the research.
• The abstract text body is limited to 3,000 characters including spaces (about 400 words or more, depending on spacing).
• Tables, Figures: Please do not insert tables into the body of the abstracts. They will need to be uploaded as files in the Figures section. A maximum of two figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure. Make sure you submit your figure with no surrounding white space and the text is readable.
• By submitting an abstract to IPITA 2027, the submitter consents to having the abstract, if accepted, published in the online supplement of the Transplantation Journal as well as in the Congress Web App.
• Only registered presenters will have their accepted abstracts published.
• It is the submitter’s responsibility to ensure that all co-authors approve of the abstract submission, publication, and potential presentation at IPITA 2027.
• Presenters who are employees of commercial interests, selected for an oral or a poster presentation, may be required to submit additional information, including the presentation slides. Presenting content featuring clinical recommendations aligned to the business interests and/or products of the employer is strictly prohibited.

Abstracts must be comprised of four distinct sections:

• Background: Describes previous research and the rationale for the current study
• Methods: Describes how the study was conducted
• Results: Describes the results of the study
• Conclusion: Summarizes the study and discusses its implications

Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.

The congress welcomes the submission of abstracts previously presented at national, regional or international meetings in the two years preceding the congress. Encores must be documented as such at the time of submission. To be accepted, the abstract must include significant additional data from the previous presentation/s. Submission will not be permitted if a manuscript has been published.

The Congress regards plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author will be rejected. In addition, the submitting author’s profile and award application, in the case one has been submitted, will also be cancelled.

To be eligible to submit an abstract, you must disclose that the author(s)/scientist(s) have not violated any aspect of the following Ethics Statement:

• The Declaration of Istanbul (DOI) ethics' statement
• Research conforms with the ethical statement on human research subject, Helsinki Declaration of The World Medical Association
• The Ethics of Xenotransplantation (Xenotransplantation 10:194-203, 2003) For research involving human subjects - The Helsinki.
• The Transplantation Society (TTS) Ethics statement

The IPITA 2027 Program Committee may require further information on the ethical aspects when evaluating the abstracts.

Authors may use AI tools to assist with language editing and clarity. However, all scientific content — including data, results, and conclusions — must be original and the authors' own. Authors are responsible for the accuracy and integrity of their abstract. Please disclose any use of AI in the "Acknowledgements" section during submission.

• All submitted abstracts will go through blind peer-review carried out by the international committee
• All abstracts will be reviewed by at least three international referees selected by the Scientific Program Committee
• Abstracts which do not meet the focus of the topic selected by the authors will be reassigned at the discretion of the Review Committee
• Abstracts will be assessed based on the following criteria:
  • Interest: Is the content original/important/relevant to our field?
  • Novelty: How and to what extent are the findings likely to influence clinical or research practice, education or policy?
  • Robustness and quality of the data: Are the methods/ methodological approach clearly described?  How confident is the reviewer in the strength/trustworthiness of the data and/or conclusions/discussion presented?
  • Presentation and Clarity: The basic purpose of the research/project is clear

Abstracts may be submitted for oral presentation (7 min + 3 min Q&A) or posters (scheduled Poster Discussions during coffee breaks).

You will be able to indicate your preferred presentation type during the submission process. However, the final presentation format will be determined by the Scientific Program Committee.

Each presenting author may present a maximum of two abstracts at the congress: two oral OR one oral and 1 poster OR 2 posters. The number of submissions is however not limited. Should an author have more than two abstracts accepted, a co-author must be named as presenting author for one or more abstracts.

Notification of acceptance or rejection will be sent to the presenting author (not submitting author) by Thursday, February 25, 2027. Please note that only the presenting author will receive the communication concerning the abstract and is responsible for informing all co-authors of the status of the abstract and register by the deadline.